Josephson David, Pasin Erik, Stein John P
University of Southern California, Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90089-9178, USA.
Expert Rev Anticancer Ther. 2007 Apr;7(4):567-81. doi: 10.1586/14737140.7.4.567.
In the second section of a two-part article, the recent literature is reviewed and the management of nonmuscle-invasive transitional cell carcinoma of the bladder is discussed. Particular attention is given to the indications and timing of intravesical chemotherapy and immunotherapy and the differences in efficacy and side-effect profiles of the available agents. The indications and role of second-look transurethral resection are reviewed. Additionally, the role of bacillus Calmette-Guerin in the management of this disease in terms of definitive treatment and maintenance therapy is discussed. We also offer a review of the literature regarding therapies for bacillus Calmette-Guerin-refractory nonmuscle-invasive transitional cell carcinoma of the bladder and their current place in practice.
在一篇分两部分的文章的第二部分中，回顾了近期的文献，并讨论了膀胱非肌层浸润性移行细胞癌的管理。特别关注膀胱内化疗和免疫治疗的适应证和时机，以及现有药物在疗效和副作用方面的差异。回顾了二次经尿道切除术的适应证和作用。此外，还讨论了卡介苗在该疾病的确定性治疗和维持治疗中的作用。我们还综述了关于卡介苗难治性膀胱非肌层浸润性移行细胞癌治疗方法及其当前临床应用地位的文献。
